Yanling Wu

5.3k total citations · 2 hit papers
64 papers, 2.9k citations indexed

About

Yanling Wu is a scholar working on Infectious Diseases, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Yanling Wu has authored 64 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Infectious Diseases, 22 papers in Radiology, Nuclear Medicine and Imaging and 18 papers in Molecular Biology. Recurrent topics in Yanling Wu's work include Monoclonal and Polyclonal Antibodies Research (22 papers), SARS-CoV-2 and COVID-19 Research (16 papers) and Immune Cell Function and Interaction (10 papers). Yanling Wu is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (22 papers), SARS-CoV-2 and COVID-19 Research (16 papers) and Immune Cell Function and Interaction (10 papers). Yanling Wu collaborates with scholars based in China, United States and Japan. Yanling Wu's co-authors include Tianlei Ying, Shibo Jiang, Lu Lu, Shuai Xia, Zheng‐Li Shi, Zhenlin Yang, Xiaolong Tian, Ailing Huang, Cheng Li and Annoor Awadasseid and has published in prestigious journals such as Journal of the American Chemical Society, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Yanling Wu

57 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

2020 838 citations Xiaolong Tian, Cheng Li et al. Emerging Microbes & Infections profile →
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

2020 518 citations Shuai Xia, Yun Zhu et al. Cellular and Molecular Immunology profile →

Peers

Countries citing papers authored by Yanling Wu

Since Specialization

Citations

This map shows the geographic impact of Yanling Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanling Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanling Wu more than expected).

Fields of papers citing papers by Yanling Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanling Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanling Wu. The network helps show where Yanling Wu may publish in the future.

Co-authorship network of co-authors of Yanling Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Yanling Wu. A scholar is included among the top collaborators of Yanling Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanling Wu. Yanling Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Topical delivery of a human single-domain antibody targeting IL-33 to inhibit mucosal inflammation 2025 ·Cellular and Molecular Immunology ·Keke Huang, Yuqing Wu, Yu Kong, (unknown), (unknown), (unknown), (unknown), Quanxiao Li, Cheng Li, Wenping Song, Xiaoyi Zhu, Zhenlin Yang, Changchang Xin, Xujiao Zhou, Tianlei Ying, Yanling Wu, Jiaxu Hong	2
2	Enhancing vaccine half-life as a novel strategy for improving immune response durability of subunit vaccines 2025 ·PLoS Pathogens ·(unknown), Cheng Li, Wenping Song, (unknown), Yu Kong, Ailing Huang, Qiyuan Bao, Tianlei Ying, Yanling Wu	0
3	Oral Administration of Trifluoroacetyl Chitosan–Encapsulated Redshifted Immunofluorophore for NIR‐II Bioimaging of Colorectal Metastases 2025 ·Advanced Healthcare Materials ·(unknown), Xiaoyi Zhu, Qingyuan Xu, Yanling Wu, (unknown), Xin Zhao, (unknown), Wei Feng, (unknown), Tianlei Ying, Zhenlin Yang	0
4	Pretrainable geometric graph neural network for antibody affinity maturation 2024 ·Nature Communications ·Huiyu Cai, (unknown), (unknown), (unknown), Quanxiao Li, (unknown), Yanling Wu, Tianlei Ying, (unknown)	12
5	Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate 2024 ·PubMed ·Xiaojie Ma, (unknown), Tianlei Ying, Yanling Wu	12
6	A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity 2023 ·Acta Pharmacologica Sinica ·Xiaoyi Zhu, Quanxiao Li, Yu Kong, Keke Huang, Gang Wang, (unknown), Jun Lu, Guoqiang Hua, Yanling Wu, Tianlei Ying	13
7	An antigen-strengthened dye-modified fully-human-nanobody-based immunoprobe for second near infrared bioimaging of metastatic tumors 2022 ·Biomaterials ·Yibing Shi, Huifang Wu, Weiqiang Hu, Yujia Jin, Mengya Kong, Yulu Wang, (unknown), Quanxiao Li, (unknown), Zhenlin Yang, Fuyou Li, Yanling Wu, Tianlei Ying	6
8	Ultraprecise Antigen 10-in-1 Pool Testing by Multiantibodies Transistor Assay 2021 ·Journal of the American Chemical Society ·Changhao Dai, Mingquan Guo, Yanling Wu, Banpeng Cao, Xuejun Wang, Yungen Wu, Kang Hua, Derong Kong, Zhaoqin Zhu, Tianlei Ying, Yunqi Liu, Dacheng Wei	64
9	Ultrasensitive Detection of SARS-CoV-2 Antibody by Graphene Field-Effect Transistors 2021 ·Nano Letters ·Kang Hua, Xuejun Wang, Mingquan Guo, Changhao Dai, Renzhong Chen, Lei Yang, Yanling Wu, Tianlei Ying, Zhaoqin Zhu, Dapeng Wei, Yunqi Liu, (unknown), (unknown)	96
10	Insights into biological therapeutic strategies for COVID-19 2021 ·Fundamental Research ·Xiaolong Tian, Cheng Li, Yanling Wu, Tianlei Ying	0
11	Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines 2021 ·Biomedicine & Pharmacotherapy ·Annoor Awadasseid, Yanling Wu, Yoshimasa Tanaka, Wen Zhang	36
12	Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody breakdown → 2020 ·Emerging Microbes & Infections ·Xiaolong Tian, Cheng Li, Ailing Huang, Shuai Xia, (unknown), Zheng‐Li Shi, Lu Lu, Shibo Jiang, Zhenlin Yang, Yanling Wu, Tianlei Ying	838
13	Current advances in the development of SARS-CoV-2 vaccines 2020 ·International Journal of Biological Sciences ·Annoor Awadasseid, Yanling Wu, Yoshimasa Tanaka, Wen Zhang	113
14	Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein breakdown → 2020 ·Cellular and Molecular Immunology ·Shuai Xia, Yun Zhu, Meiqin Liu, Qiaoshuai Lan, Wei Xu, Yanling Wu, Tianlei Ying, Shuwen Liu, Zheng‐Li Shi, Shibo Jiang, Lu Lu	518
15	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response 2020 ·Signal Transduction and Targeted Therapy ·Zezhong Liu, Wei Xu, Shuai Xia, Chenjian Gu, Xinling Wang, Qian Wang, Jie Zhou, Yanling Wu, Xia Cai, Di Qu, Tianlei Ying, Youhua Xie, Lu Lu, Zhenghong Yuan, Shibo Jiang	140
16	SARS-CoV-2 variants evolved during the early stage of the pandemic and effects of mutations on adaptation in Wuhan populations 2020 ·International Journal of Biological Sciences ·Annoor Awadasseid, Yanling Wu, Yoshimasa Tanaka, Wen Zhang	38
17	Identification of Human Single-Domain Antibodies against SARS-CoV-2 2020 ·Cell Host & Microbe ·Yanling Wu, Cheng Li, Shuai Xia, Xiaolong Tian, Yu Kong, Zhi Wang, Chenjian Gu, Rong Zhang, Chao Tu, Youhua Xie, Zhenlin Yang, Lu Lu, Shibo Jiang, Tianlei Ying	181
18	Arming Anti-EGFRvIII CAR-T With TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models 2020 ·Frontiers in Oncology ·You Li, (unknown), Gang Chen, Xiaofan Wei, Chunyu Wang, (unknown), Ailing Huang, Zui Zhang, Changyou Zhan, Yanling Wu, Tianlei Ying	29
19	Single-Domain Antibodies As Therapeutics against Human Viral Diseases 2017 ·Frontiers in Immunology ·Yanling Wu, Shibo Jiang, Tianlei Ying	79
20	[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies]. 2016 ·PubMed ·(unknown), (unknown), Yanling Wu, (unknown), (unknown), (unknown), Xiaoyun Zhu, (unknown), (unknown), (unknown), (unknown), (unknown), Wei Yao, (unknown), (unknown), (unknown), Yang Liu, (unknown), (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact